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Abstract
The mammalian intestine harbors a complex microbial community that provides numerous 
benefits to its host. However, the microbiota can also include potentially virulent species, termed 
pathobionts, which can cause disease when intestinal homeostasis is disrupted. The molecular 
mechanisms by which pathobionts cause disease remain poorly understood. Here we describe a 
sepsis-like disease that occurs upon gut injury in antibiotic-treated mice. Sepsis was associated 
with the systemic spread of a specific multidrug-resistant E. coli pathobiont that expanded 
dramatically in the microbiota of antibiotic-treated mice. Rapid sepsis-like death required a 
component of the innate immune system, the Naip5-Nlrc4 inflammasome. In accordance with 
Koch's postulates, we found the E. coli pathobiont was sufficient to activate Naip5-Nlrc4 and 
cause disease when injected intravenously into unmanipulated mice. These findings reveal how 
sepsis-like disease can result from recognition of pathobionts by the innate immune system.
The intestinal microbiota is comprised of diverse microbial species that provide numerous 
benefits to their hosts1. However the microbiota can also contain species, termed 
`pathobionts', that can cause disease if not properly constrained1,2. A major mechanism 
constraining pathobionts is believed to be competition or suppression by the healthy 
microbiota1. Indeed, disruption of the healthy microbiota (for example, by antibiotics) can 
elicit pathobiont virulence and disease1, 3–6. Although pathobionts are believed to contribute 
to numerous disease states7–11, it has been challenging to identify the causal molecular 
mechanisms that are responsible for disease in vivo12–15.
A key orchestrator of innate immune responses are inflammasomes, multi-protein 
complexes that detect infection in the cytosol and are required for activation of the 
Caspase-1 protease, and downstream secretion of its substrates, the pro-inflammatory 
cytokines interleukin (IL)-1β and −1816. Several distinct inflammasomes have been 
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described. For example, the Naip5-Nlrc4 inflammasome detects flagellin proteins from 
diverse bacteria17,18. Recently, several reports have established a protective role for 
inflammasomes in regulating microbiota composition and tissue reparative and regenerative 
responses to intestinal injury13,19–22. Although inflammasome responses in these models are 
protective against disease, it is also well-recognized that excessive inflammation has the 
potential to be pathological. However, a potential pathological role of inflammasome 
activation in response to a disrupted intestinal flora has not yet been investigated.
Here, we established a sepsis model triggered by a dysbiotic microbiota. In response to 
intestinal injury, antibiotic-treated mice succumbed rapidly to a sepsis-like death. Death was 
associated with the systemic presence of a multi-drug resistant E. coli pathobiont that we 
isolated from the organs of septic mice. Interestingly, we found that sepsis pathogenesis 
required activation of the Naip5-Nlrc4 inflammasome. Importantly, and in accordance with 
Koch's postulates, intravenous injection of the E. coli pathobiont into normal mice 
recapitulated the rapidly fatal Naip5-Nlrc4-dependent sepsis that was observed in antibiotic-
treated mice in response to intestinal injury. Our results reveal a molecular mechanism by 
which disruptions of intestinal homeostasis can result in aberrant pathobiont-induced innate 
immune signaling and rapid sepsis-like death.
Results
Antibiotics and intestinal injury results in sepsis
To study the innate immune response to a disrupted intestinal microbiota, we established a 
disease model that couples antibiotic treatment with the dextran sulfate sodium (DSS)-
induced intestinal injury. DSS is toxic to colonic epithelial cells, and typically results in a 
colitis-like disease23 characterized by severe weight loss, colonic bleeding and colonic 
shortening (Supplementary Fig 1a, b) . We wanted to understand how antibiotic-induced 
disruption of the microbiota (dysbiosis) would influence DSS-induced disease. Oral 
administration of a broad-spectrum antibiotic cocktail composed of ampicillin, vancomycin, 
neomycin and metronidazole (`AVNM') to colony-born C57BL/6 wild-type mice resulted in 
a change in the microbiota composition and reduction in the amount of 16S rDNA gene 
copy number along the intestinal-tract (Supplementary Fig. 1c – e). After this initial 
treatment, mice were given AVNM+5% DSS and we monitored survival. Consistent with 
previous reports24, AVNM-treatment rendered wild-type mice more susceptible to DSS 
(Fig. 1a and Supplementary Fig. 1f). Interestingly, ampicillin alone was sufficient to 
increase susceptibility to DSS treatment (Supplementary Fig. 1g, h). By contrast, mice 
treated with the broad-spectrum antibiotic streptomycin were just as susceptible to DSS as 
non-antibiotic treated mice (Fig. 1b).
Although DSS typically induces colitis, we found that AVNM+DSS-treated mice did not 
exhibit the hallmark symptoms of colitis (e.g., weight loss, colonic inflammation/shortening, 
poor stool pellet formation; Fig. 1c – e and data not shown). Rather, AVNM+DSS-treated 
mice exhibited small-intestinal bleeding and hypothermia (Fig. 1f, g and Supplementary Fig. 
2a), as well as multi-organ damage (MOD) and substantial serum levels of pro-inflammatory 
cytokines including TNF-α and IL-6 (Fig. 1h and data not shown). These results suggest that 
AVNM-induced changes to the microbiota trigger a systemic disease, distinct from colitis, 
Ayres et al. Page 2
Nat Med. Author manuscript; available in PMC 2012 November 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
in response to intestinal injury. Hypothermia and MOD are associated with sepsis in 
mice25,26. Consistent with this diagnosis, we found that antibiotic-treated mice exhibited 
significantly higher levels of culturable bacteria in the lung (P < 0.05) and the liver (P < 
0.05) compared to nonantibiotic-treated mice (Fig. 1i, and Supplementary Fig. 2b, c).
To determine if the sepsis-like disease was specific to mice from our facility, we analyzed 
disease progression in AVNM+DSS-treated C57BL/6 specific pathogen free (SPF) mice 
from Jackson Laboratory (Jax mice) and Taconic farms (Taconic mice). Taconic mice 
developed hypothermia and were more susceptible to AVNM+DSS compared to DSS-only 
treated Taconic mice. Furthermore, AVNM attenuated DSS-induced colitis symptoms in 
Taconic mice (Supplementary Fig. 3a – b and data not shown). By contrast, disease in 
AVNM+DSS-treated Jax mice appeared to develop similarly to DSS-only treated Jax mice 
(Supplementary Fig. 3c – e and data not shown). Thus it appears that SPF mice from 
different facilities exhibit distinct disease symptoms in response to AVNM+DSS treatment.
Antibiotic-induced expansion of drug-resistant E. coli
Several non-exclusive models could explain how alterations in the microbiota can trigger 
disease. For example, antibiotic treatment could eliminate members of the microbiota that 
elicit protective host responses24. In addition, antibiotics could result in the overgrowth of 
AVNM-resistant pathobionts. Consistent with the latter possibility, after 7 d of AVNM-
treatment, colony-born wild-type mice harbored an expanded population of AVNM-resistant 
bacteria along the intestinal-tract (Fig. 2a). We observed a similar expansion of an AVNM-
resistant population in Taconic mice, but no detectable levels of culturable AVNM-resistant 
bacteria in Jax mice (Supplementary Fig. 3). Furthermore, we found that the AVNM-
resistant bacteria colonized extraintestinal tissues of AVNM+DSS colony-born wild-type 
mice (Fig. 2b, c and Supplementary Fig. 2). Thus, sepsis-like disease correlated with the 
intestinal expansion and extraintestinal colonization of AVNM-resistant bacteria.
We obtained an AVNM-resistant isolate from our mice that we identified as an O21:H+ 
Escherichia coli by16S rDNA sequencing, biochemical characterization, and serotyping 
(Fig. 2d, e and data not shown). An expansion of intestinal Enterobacteriaceae species in 
response to antibiotic treatment is consistent with previous reports27. AVNM-resistant E. 
coli was also recovered from the lung, liver, spleen and kidney of AVNM+DSS-treated 
colony-born mice (Fig. 2f and Supplementary Fig. 2e, f). To determine if E. coli was the 
predominant systemic AVNM-resistant species in our mice, we performed 16S rDNA 
cloning and sequencing analyses of livers and spleens from AVNM+DSS-treated colony-
born mice. Although this approach identified clones representing multiple taxa, Escherichia 
was the most abundant taxon identified, consistent with our culturing experiments. In 
addition, E. coli was the only taxon represented by all tissues from AVNM+DSS-treated 
mice analyzed (data not shown). We also identified AVNM-resistant E. coli in the intestines 
of Taconic mice (Supplementary Fig. 3). Taken together, our data demonstrate that 
antibiotic treatment facilitates the intestinal overgrowth of AVNM-resistant O21:H+ E. coli 
that can translocate to extraintestinal sites upon intestinal injury.
The E. coli-O21:H+ was present in the microbiota of unmanipulated mice (Fig. 2e), but was 
not abundant, suggesting it was not able to compete efficiently for intestinal colonization 
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with other members of the flora in the absence of antibiotics. Consistent with this 
hypothesis, we found that 1 week after cessation of AVNM treatment, the aberrant 
expansion of E. coli-O21:H+ was suppressed (Supplementary Fig. 4a), and importantly such 
mice no longer developed sepsis in response to DSS (Supplementary Fig. 4b, c).
As streptomycin-treated mice did not exhibit rapid sepsis-like death in response to DSS (Fig. 
1b), we hypothesized that our AVNM-resistant E. coli isolate is sensitive to streptomycin. 
Indeed we found that our E. coli-O21:H+ isolate is sensitive to streptomycin and is 
eliminated from mice by streptomycin treatment (Fig. 2d, g). Taken together, these data 
clearly demonstrate that the increased sensitivity to AVNM+DSS and development of sepsis 
is associated with intestinal overgrowth and extraintestinal colonization of AVNM-resistant 
E. coli-O21:H+.
Because Jax mice do not appear to be colonized with AVNM-resistant E. coli-O21:H+, we 
could determine if this bacterium and its associated disease phenotype are transmissible. We 
co-housed Jax mice with colony-born mice and treated with AVNM for 7 d, after which co-
housed Jax mice exhibited AVNM-resistant E. coli colonization levels comparable to 
colony-born co-housed mice. By contrast, single-housed Jax mice had no detectable levels 
of AVNM-resistant E. coli (Fig. 2h). Importantly, upon induction of intestinal injury, co-
housed Jax mice exhibited increased susceptibility to DSS, similar to colony-born mice, and 
unlike single-housed Jax mice (Fig. 2i). These results demonstrate that E. coli-O21:H+ and 
the associated sepsis phenotype are transmissible.
Systemic E. coli infection is sufficient to induce sepsis
To determine if our E. coli-O21:H+ isolate is sufficient to cause disease in wild-type mice, 
we orally infected AVNM-treated Jax mice with E. coli-O21:H+. Oral administration of E. 
coli-O21:H+ to antibiotic treated Jax mice resulted in high levels of colonization 
(Supplementary Fig. 4d). Furthermore, colonized Jax mice developed hypothermia that was 
associated with reduced colitis symptoms compared to AVNM+DSS-treated mice that 
received a PBS oral challenge (Supplementary Fig. 4e).
To determine if the E. coli-O21:H+ isolate is sufficient to cause disease in wild-type mice 
with a normal (non-antibiotic treated) microbiota, we intravenously injected normal B6 mice 
with live or dead E. coli-O21:H+ and monitored disease. Mice were highly susceptible to a 
systemic challenge of live but not heat-killed bacteria (Fig. 3a). In addition, systemic live E. 
coli-O21:H+ infection was sufficient to recapitulate the specific pathology associated with 
AVNM+DSS treatment (Fig. 3b, c). Furthermore, live E. coli-infected mice exhibited tissue 
colonization patterns and levels similar to what was observed in AVNM+DSS-treated wild-
type mice (Fig. 1i, 3d and Supplementary Fig. 2b, c). Thus, in fulfillment of Koch's 
postulates, a live systemic infection with E. coli-O21:H+ is sufficient to recapitulate the 
mortality and morbidity associated with AVNM+DSS-induced sepsis.
E. coli-O21:H+ harbors virulence factors
E. coli O21 isolates have been obtained from patients with extraintestinal infections 
including bacteraemia/sepsis28–32. We therefore hypothesized that the E. coli pathobiont 
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encodes virulence factors mediating its pathogenicity in wild-type mice. Consistent with this 
hypothesis, disease was attenuated in mice infected with a non-pathogenic E. coli-K12 strain 
(MG1655), as compared to our E. coli-O21:H+ isolate, (Fig. 3 e, f), suggesting that 
detection of viable, nonpathogenic strains of E. coli by the immune system33 is not sufficient 
to trigger the sepsis-like disease in wild-type mice.
To identify further virulence-associated determinants, we sequenced the genome of our E. 
coli-O21:H+ isolate and aligned the reads to reference E. coli genomes (Supplementary 
Table 1). The fliC gene, encoding flagellin (H-antigen), was most similar to that of H21 
isolates (Supplementary Fig. 5a). In addition, alignment to the E. coli O157:H7 strain Sakai 
reference genome revealed that our O21:H+ isolate harbors a cluster of genes exhibiting 
similarity to the ETT2 type III secretion system (T3SS)34 (Supplementary Fig. 5b). Many 
septicemic E. coli isolates encode a unique version of the ETT2 gene cluster called 
ETT2sepsis35 that contains a large deletion in the eiv gene cluster (cluster E in 
Supplementary Fig. 5b), creating deletions and truncations for the majority of eiv genes35. 
Despite this, ETT2sepsis is essential for sepsis pathogenesis, as mutations in ETT2sepsis 
render septicemic E. coli avirulent35. Interestingly, we were unable to align genomic content 
of the E. coli-O21:H+ genome to an 8.7 kb region of the ETT2 gene cluster that contains the 
eiv genes, suggesting that E. coli-O21:H+ harbors a form of the ETT2sepsis gene cluster 
(Supplementary Fig. 5b).
We also found that E. coli-O21:H+ encodes additional factors associated with bacteremic/
septic E. coli clinical isolates including those important for adhesion (papC, fim gene cluster 
and pil gene cluster), internalization (csg genes) and iron acquisition (enterobactin and 
ferrichrome gene clusters)35–43. The genome also encodes the malX (marker for 
pathogenicity associated island from strain CFT073)38. Thus, the genome of E. coli-O21:H+ 
encodes a number of factors associated with bacteremic/septicemic clinical E. coli isolates.
Naip5-Nlrc4 inflammasome mediates AVNM/DSS–induced sepsis
Since pathogenic E. coli were previously reported to activate inflammasomes containing 
Naip and Nlrc4 proteins44,45, we hypothesized that the Naip5-Nlrc4 inflammasome might 
mediate disease in our sepsis model. Indeed, we found AVNM+DSS-induced disease 
progression was highly attenuated in Nlrc4−/−Naip5−/− mice (Fig. 4a – e). Importantly, 
AVNM-treated Nlrc4−/− Naip5−/− mutant mice exhibited similar levels of AVNM-resistant 
E. coli overgrowth in the intestinal tract as wild-type fostermates prior to DSS treatment, 
implying that inflammasome-deficiency did not exert its protective effects by modulating 
bacterial growth (Figure 4f and Supplementary Fig. 6a, b). Moreover, the organs of AVNM
+DSS-treated Nlrc4−/−Naip5−/− were colonized with similar levels of AVNM-resistant E. 
coli as wild-type mice (Figure 4g and Supplementary Fig. 6c, d). These data indicate that the 
absence of Naip5-Nlrc4 function protects AVNM+DSS-treated mice from developing sepsis 
at a step after extraintestinal dissemination of E. coli-O21:H+. Since Nlrc4−/−Naip5−/− mice 
eventually succumb to AVNM+DSS-induced sepsis, it is likely that additional host factors 
also contribute to disease.
The Naip5-Nlrc4 inflammasome generally detects flagellin translocated to the host cell 
cytosol via type III or IV secretion systems44. Because E. coli-O21:H+ encodes a T3SS and 
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a functional flagellin (FliC) (Fig. 5a and Supplementary Fig. 5) similar to pathogenic E. coli 
species, we hypothesized that the cytosolic presence of flagellin from this pathobiont can 
activate the Naip5-Nlrc4 inflammasome. We tested this hypothesis using a previously 
described retroviral `lethality' assay44 in which flagellin is expressed from a retroviral 
promoter directly in host cells, allowing for analysis of the effects of flagellin in the absence 
of other bacterial factors. Wild-type, Nlrc4−/− and Naip5−/− bone marrow derived 
macrophages were retrovirally transduced with fliC-IRES-GFP, control GFP, or control L. 
pneumophila flagellin (flaA-IRES-GFP). Activation of Naip5-Nlrc4 by flagellin results in 
cell death, as indicated by the loss of GFP positive cells. As previously reported, cells 
expressing L. pneumophila flaA-IRES-GFP could only be recovered from Nlrc4−/− 
macrophages46. Detection of FlaA by Naip6 likely accounts for the residual responsiveness 
of Naip5−/− cells. However cells expressing E. coli-O21:H+ fliC-IRES-GFP could be 
recovered from both Nlrc4−/− and Naip5−/− macrophages, but not wild-type macrophages 
(Fig. 5b, c). These data demonstrate that cytosolic flagellin derived from E. coli-O21:H+ 
activates the Naip5-Nlrc4 inflammasome and triggers host cell death.
Naip5-Nlrc4 inflammasome reduces host tolerance of E. coli
To address Koch's Postulates we infected wild-type and Nlrc4−/−Naip5−/− mice 
intravenously with E. coli-O21:H+. Systemic E. coli-O21:H+ infection was significantly 
less lethal in the absence of Naip5-Nlrc4 function (P = 0.0001) (Fig. 6a and Supplemental 
Fig. 7a, b). The absence of Naip5-Nlrc4 function also alleviated the pathologies associated 
with E. coli-O21:H+ infection (Fig. 6b – d). Furthermore, E. coli-O21:H+ infection was 
attenuated in Caspase1−/− and Il-1β−/− mice (Fig. 6e and Supplementary Fig. 7c, d). 
Additionally, systemic administration of anti-IL-1 receptor antibody protected mice from 
disease AVNM+DSS-induced disease (Fig. 6f). Thus, the absence of IL-1β is sufficient to 
protect mice from a systemic inflammatory response induced by a systemic E. coli-O21:H+ 
infection (Fig. 6e and Supplementary Fig. 7d). Taken together, our data clearly demonstrate 
that Naip5-Nlrc4 inflammasome signaling through IL-1β in response to a systemic E. coli-
O21:H+ infection leads to sepsis.
The greater susceptibility of wild-type (as compared to Naip5−/−Nlrc4−/−) mice to E. coli-
O21:H+ infection was not associated with higher levels of extraintestinal bacterial 
colonization (Fig. 6g). In fact, colonization levels were similar in both genotypes. Thus we 
conclude that mice lacking Naip5-Nlrc4 fare better in response to a systemic E. coli-O21:H+ 
infection because they exhibit increased tolerance of the infection47, rather than because of 
negative effects on pathogen fitness.
Discussion
We describe a mouse model of sepsis triggered by dysbiosis and intestinal injury. This 
model resembles the clinically significant sepsis that is a major problem in human patients 
undergoing combination therapies involving antibiotics and cytotoxic treatments that 
damage the gut epithelium48. Consistent with the defining features of sepsis, we found that 
disease in AVNM+DSS-treated mice is characterized by systemic dissemination of bacteria, 
multi-organ damage, and systemic responses, such as hypothermia. A key conclusion of our 
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study is that sepsis in our AVNM+DSS-treated mice is due to inflammasome activation by a 
specific multi-drug resistant E. coli-O21:H+ pathobiont. This pathobiont exists in the normal 
unmanipulated flora, but expands dramatically in the gut upon antibiotic treatment, and 
reaches systemic sites following DSS-induced intestinal injury (Supplementary Fig. 7e). In 
accordance with Koch's postulates, we show definitively that the systemic presence of this 
pathobiont is sufficient to induce sepsis-like disease.
Similar to our findings, a previous report demonstrated that antibiotic pre-treatment rendered 
mice more susceptible to DSS treatment24. However, this report proposed that disease in 
AVNM+DSS-treated mice is not associated with systemic spread of bacteria, but is instead 
due to a failure to receive appropriate TLR-dependent signals needed to repair gut epithelial 
injury. Consistent with this interpretation, it was found that disease could be alleviated by 
the oral administration of LPS, suggesting that TLR signaling plays an important protective 
role24. By contrast, in our model, mice given AVNM+DSS exhibited symptoms of sepsis, 
not colitis, and oral administration of LPS was not sufficient to prevent sepsis 
(Supplementary Fig. 2d). Indeed, dysbiosis in the AVNM+DSS model may both reduce the 
levels of beneficial microbes, as well as result in an expansion of pathobionts. The apparent 
discrepancy between our work and the prior study24 may be explained by differences in 
microbial flora in the mice, as well by methodological differences. For example, the 
previous study utilized a 7 d treatment of 2% DSS, which produces milder damage that mice 
are able to repair. In our model, we used a continuous dose of 5% DSS. Nevertheless, since 
systemic infection of normal mice with E. coli-O21:H+ is sufficient to recapitulate the 
AVNM+DSS disease model, we favor the hypothesis that pathology in our mice is driven 
primarily by an E. coli pathobiont.
Prior studies have demonstrated a protective role for the inflammasome in mediating 
pathogen resistance45,49 and in inducing tissue repair20,21. By contrast, our study 
demonstrates that excessive or systemic inflammasome-mediated recognition of a bacterium 
can lead to pathology and death. In our model, inflammasome activation results in IL-1β-
driven immunopathology that the host cannot tolerate (Supplementary Fig. 7). The 
dependence on IL-1β distinguishes our sepsis model from others including LPS 
endotoxemia (Supplementary Fig. 7)50–52. Blockade of IL-1 signaling has long been 
considered a potential therapeutic treatment for human sepsis, but has met with little success 
in clinical trials53,54. This is likely because sepsis is a complex disease involving diverse 
microbes and host immune pathways. Our results highlight the importance of experimentally 
defining the relevant pathogenic pathways for different microbial causes of sepsis, and 
identifying the causative agents of sepsis in human patients.
Antibiotic-resistant E. coli present a challenge to antimicrobial medical interventions4. Our 
finding that mice lacking inflammasome components exhibit increased tolerance of systemic 
E. coli infection may have important therapeutic implications. Tolerance is a defense 
strategy that allows a host to endure an infection without influencing microbial load47,55. 
Tolerance contrasts with resistance, which protects a host by decreasing pathogen 
burden47,55. We propose that the inflammasome may be an alternative therapeutic target for 
patients exhibiting pathology due to antibiotic-resistant pathobionts. An important benefit of 
therapeutic modulation of host tolerance is that microbes are not predicted to evolve 
Ayres et al. Page 7
Nat Med. Author manuscript; available in PMC 2012 November 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
antagonistic traits to such therapeutics, in contrast to standard antimicrobials47,56,57. Taken 
together, our results provide insight into the mechanisms by which a specific constituent of a 
dysregulated flora can cause disease by inappropriate inflammasome activation.
Online Methods
Mice
Naip5−/− mice were generated as described previously44. Nlrc4−/− mice were from S. 
Mariathasan and V. Dixit58. We crossed Naip5−/− and Nlrc4−/− mice to each other to 
generate double knockout mice. Caspase-1-deficient (Casp1−/−) mice were a gift from A. 
Van der Velden and M. Starnbach59. Il-1β−/− mice were from the Zychlinsky Lab at Max 
Planck Institute. Gene targeted mice were on a C57BL/6 (B6) background. Wild-type B6 
mice were originally obtained from the Jackson Laboratories, but all colony-born mice used 
were bred in our mouse facility for at least 10 generations. All mice were specific pathogen 
free, maintained under a 12 h light-dark cycle (7 a.m. to 7 p.m.) and given a standard chow 
diet (Harlan irradiated laboratory animal diet) ad libitum. For experiments involving 
littermate mice, we crossed Naip5+/−Nlrc4+/− mice to generate Naip5−/− Nlrc4−/− and 
Naip5+/+Nlrc4+/+ littermates. For fostermate mice, we placed wild-type pups with the 
mutant litter within 48 h of birth to nurse on the Naip5−/− Nlrc4−/− mother. Pups were 
weaned at 21 d of age. Animal experiments were approved by the University of California, 
Berkeley, Animal Care and Use Committee.
Survival assays
We used time to moribund for all survival assays. We identified moribund mice as those 
mice exhibiting ataxia severe enough such that the animals could not recover (unable to 
move when gently touched, or experience trouble self-correcting when placed on their side). 
Moribund mice were euthanized in compliance with the Animal Care and Use Committee at 
UC Berkeley.
DSS colitis model
We transferred 6 w old littermates to new cages and gave them drinking water supplemented 
with 5% DSS (w/v) (M.W. = 36,000–50,000 Da; MP Biomedicals) continuously for the 
duration of the experiment. We measured disease severity by monitoring weight daily, and 
colon length was measured at 6 d post DSS treatment initiation and survival (time to 
moribund).
Antibiotic/DSS sepsis model
At 5 w of age, we transferred littermates or fostermates to new cages and gave them 
drinking water supplemented with a combination of ampicillin (1 g L−1), neomycin (1 g 
L−1), metronidazole (1 g L−1) and vancomycin (0.5 g L−1), ampicillin only (1 g L−1) or 
streptomycin only (2 g L−1) for 7–10 d (Sigma Aldrich). After this initial antibiotic 
treatment, we gave mice drinking water supplemented with the appropriate antibiotic at the 
abovementioned concentration plus 5% DSS (w/v) continuously over the course of the 
experiment. We monitored mice for signs of disease including weight loss and colonic 
shortening as described above, rectal temperature, and serum analysis of organ damage as 
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well as bacterial extraintestinal tissue colonization. For LPS+AVNM+DSS administration, 
we gave mice drinking water supplemented with AVNM/5% DSS and 10 μg ml−1 LPS 
O55:B5 (Sigma) after an initial 10 d AVNM treatment.
E. coli in vivo infections
We grew E. coli overnight in LB media shaking at 37 °C. We transferred age-matched 
female mice to new cages and injected them intravenously with 5×108, 7.5×108 or 1×109 
live bacteria in PBS and gave them food and water ad libitum. We monitored body 
temperature and survival (time to moribund). For injections with dead bacteria, we prepared 
inoculums at the appropriate concentration in PBS and incubated at 65 °C for 30 min to heat 
kill the bacteria. For E. coli K12 infections, we grew E. coli overnight in LB media shaking 
at 37 °C. We transferred age-matched female mice to new cages and injected them 
intravenously with 5×108 bacteria in PBS and gave them food and water ad libitum.
Body Temperature
We monitored body temperature using a rectal probe and microtherma thermometer 
(Braintree Scientific). We lubricated the probe with a water-based lubricant (Astroglide) 
prior to use.
Serum Analysis
We euthanized mice and obtained blood by cardiac puncture at the indicated time points. We 
then aliquoted blood into BD serum separator tubes, incubated at room temperature for 20 
min and centrifuged at 2.6 rpm for 20 min. We stored serum at −80 °C until analysis. BUN, 
CPK, AST and ALT measurements were done by IDEXX Laboratories.
Bacterial culturing
For compositional analysis of the intestinal tract and extraintestinal tissues, we harvested 
whole tissues and homogenized them using a Polytron PT2100 homogenizer at 17000 rpm 
(Kinematica) in sterile thioglycolate media. We then serially diluted the homogenate and 
plated on LB agar and schaedler agar supplemented with 5% defibrinated sheep blood plates 
and grew at 37 °C aerobically and anaerobically for 24 h. We counted bacterial colonies and 
then separated based on colony appearance and performed colony 16S rDNA PCR and 
sequencing (see below).
For cultivation of Enterobacteriales species, we harvested and homogenized intestinal and 
extraintestinal tissues from AVNM+DSS mice as described above. We then serially diluted 
the homogenates and plated them on bacterial medias that support the growth of 
Enterobacteriales including LB, Maconkey, and EMB. We then incubated the plates 
aerobically at 37 °C for 24 h, after which we counted colonies, classified based on colony 
appearance and subjected them to 16S rDNA colony PCR and sequencing (see below). We 
then tested isolates for antibiotic susceptibility (see below).
For CFU analysis of E. coli in AVNM+DSS-treated and E. coli-O21:H+ infected mice, we 
harvested and homogenized intestinal and extraintestinal organs in sterile PBS, serially 
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diluted and plated on EMB or LB plates containing AVNM and incubated them at 37 °C for 
24 h.
Colony PCR
We resuspended colonies in sterile PBS, boiled for 10 min at 100 °C. We used this directly 
for PCR analysis with the universal bacterial primers 27F (5′-
AGAGTTTGATCCTGGCTCAG-3′) and 1492R (5′-GGTTACCTTGTTACGACTT-3′)60. 
We performed PCR on a Bio-Rad iCycler using an annealing temperature of 51 °C and the 
following conditions: 95 °C (5 min), followed by 30 cycles of 95 °C (30 s), annealing (1 
min), 72 °C (2 min), and a final extension at 72 °C (10 min). Reactions were then subjected 
to a PCR cleanup using the QIAquick PCR Purification Kit (Qiagen) and sequenced using 
the 1492R primer (Elim Biopharm). We classified the sequences using the Michigan State 
University Ribosomal Database Project classifier function (http://rdp.cme.msu.edu/).
Antibiotic susceptibility assays
We determined E. coli-O21:H+ susceptibility to AVNM and streptomycin using a disc 
diffusion assay. We inoculated liquid cultures with E. coli and grown at 37 °C with shaking 
overnight. We placed aliquots of cultures onto LB agar plates and 6 mm Whatman discs 
loaded with the appropriate antibiotic onto the agar. We incubated plates overnight at 37 °C 
and measured the zone of bacterial growth inhibition. Antibiotic susceptibility profiling of 
the isolate was also performed by Jeffrey Schapiro and James LaPan of the Clinical 
Microbiology Laboratory at Kaiser Permanente (Berkeley, CA). E. coli DH5α was used as a 
control.
16S rDNA quantitative PCR analyses
We treated mice with regular drinking water or drinking water supplemented with AVNM 
for 7–10 d. We then harvested intestinal tissues, snap froze them in liquid nitrogen and 
stored them at −80 °C prior to analysis. We extracted DNA using the Qiagen Stool Kit per 
manufacturer's instructions with a bead-beating step. Specifically, we put whole tissues into 
Lysing Matrix E tubes (MP Biomedicals) with 1.4 ml of buffer ASL and subjected to three 
cycles of shaking for 3 min using a Vortex Genie 2. We placed samples on ice for 3 min in 
between cycles. We extracted DNA from the resulting supernatants per manufacturer's 
protocol. We quantified purified DNA on a Nanodrop 1000 (Thermo Scientific) and then 
performed quantitative PCR assays on the Step One Plus RT PCR system (Applied 
Biosystems) with the iTaq SYBR Green Supermix with Rox reagent (Bio–Rad). We 
normalized 16S gene copy numbers to Rps17 (mouse). We used the following primer 
sequences: mouse Rps17F (5′- CGCCATTATCCCCAGCAAG-3′) and Rps17R (5′-
TGTCGGGATCCACCTCAATG-3′); bacteria universal 16S rDNA uniF340 (5′-
ACTCCTACGGGAGGCAGCAGT-3′) and uniR514 (5′-
ATTACCGCGGCTGCTGGC-3′)61; Enterobacteriaceace 16S rDNA specific 515F (5′-
GTGCCAGCMGCCGCGGTAA-3′) and 826R (5′-
GCCTCAAGGGCACAACCTCCAAG-3′)61; Bacteroides 16S rDNA specific BactF285 (5′-
GGTTCTGAGAGGAGGTCCC-3′) and UniR338 (5′-GCTGCCTCCCGTAGGAGT-3′)61; 
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Actinobacteria 16S rDNA specific Actino235F (5′-CGCGGCCTATCAGCTTGTTG-3′) and 
Eub518R (5′-ATTACCGCGGCTGCTGG-3′)62.
Motility Assay
We inoculated single colonies of bacteria at a single point on soft motility LB agar (0.35%) 
and incubated overnight at 37 °C. As controls, we used S. Typhimurium strain LT2 and the 
flagellin mutant S. Typhimurium LT2 ΔfliCΔfljB (A. Van Der Velden and M. Starnbach).
Retroviral constructs and transductions
We produced retroviral constructs and executed transductions as previously described44. 
Briefly, we generated retroviral particles by the transient transfection of Phoenix–Eco 
packaging cells with MSCV2.2-based retroviral vectors. We cultured bone marrow–derived 
cells (1×106) for 48 h in a 6-well Falcon brand non-tissue culture treated plate in medium 
containing macrophage colony-stimulating factor (M-CSF) and then we transduced cells 
with 2 ml of retrovirus–containing packaging cell supernatant. 24 h after the initial infection, 
we infected bone marrow-derived cells once again with 2 ml of retrovirus–containing 
packaging cell supernatant. We analyzed macrophages 4 d post-transduction and analyzed 
for GFP expression on a Beckman Coulter FC-500 flow cytometer. We analyzed more than 
25,000 cells per sample. We cloned the E. coli-O21:H+ fliC gene using the primers fliC 
XhoI (5′-AAAACTCGAGGCCACCATGGCACAAGTCATTAATAC-3′) and fliC NotI (5′- 
TTTTGCGGCCGCTTAACCCTGCAGCAGAAG-3′)
LPS injections
We injected age-matched female wild-type and Il-1β−/− mice intravenously with 5 mgkg−1 
LPS O55:B5 (Sigma) and given food and water ad libitum. We monitored Survival (time to 
moribund).
E. coli-O21:H+ Serotyping
Serotyping was done at the E. coli reference center, Pennsylvania State University.
Experiments with commercial vendor mice
For disease analyses, we kept mice in autoclaved isolator cages and gave them sterile–
filtered AVNM or water for 7 d followed by treatment with sterile-filtered AVNM+5% DSS 
or 5% DSS-only. We monitored weight, temperature and survival (time to moribund). For 
CFU analyses, upon receipt, we immediately dissected mice or put them in autoclaved 
isolator cages and gave them sterile-filtered drinking water with AVNM for 7 d, after which 
intestines were dissected. We plated homogenized tissues on AVNM+EMB plates, 
enumerated colony types and subjected them to 16S rDNA PCR and sequencing and 
genotyped for eprJ. Separate shipments of mice were received for each experimental 
replicate.
Horizontal Transfer Experiments
We obtained 5 w old C57BL/6 male mice were obtained from Jackson Laboratories 
(Sacramento, CA) and kept them single-housed in isolator cages or co-housed in isolator 
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cages with age and sex-matched C57BL/6 mice bred in our colony. We then treated mice 
with AVNM ad libitum for 7 d, after which we harvested and homogenized intestinal tissues 
and plated them on EMB agar plates supplemented with AVNM to determine the levels of 
AVNM-resistant bacteria colonization. To analyze disease severity (temperature, body 
weight and time to moribund), we gave mice given drinking water supplemented with 
AVNM+5% DSS after the initial 7 d course of AVNM treatment. We compared disease 
severity to single–housed controls.
Oral infection of commercially purchased mice
We obtained 5 w old C57BL/6 female mice from Jackson Laboratory (Sacramento, CA), 
kept them in isolator cages and treated them with AVNM ad libitum for 7 d. On 4, 5 and 6 d, 
we gavaged mice with 200 μl of an overnight culture of E. coli-O21:H+, washed and 
resuspended to 2.5×109 in sterile PBS. We gavaged control mice with 200 μl of sterile PBS. 
On 7 d, we either dissected mice for CFU analysis or gave them drinking water 
supplemented with AVNM+5% DSS and monitored temperature and weight.
Whole genome sequencing of E. coli O21:H+
Library preparation, Illumina HiSeq 2000 SE50 sequencing and mapping were done by the 
Tufts Core Facility (TUCF) at Tufts Univeristy. For library preparation, we grew E. coli 
overnight in LB media shaking at 37 °C and isolated genomic DNA using the Qiagen 
DNeasy kit and submitted DNA to TUCF for library preparation and sequencing. Reads 
were aligned to eleven publicly available E. coli whole–genome sequences (E. coli HS 
CP000802, E. coli E24377A ETEC NC_009801, E. coli 53638 EIEC AAKB00000000, E. 
coli 042 EAEC FN554766, E. coli O127:H6 EPEC NC_011601, E. coli IAI39 ExPEC 
NC_011750, E. coli S88 ExPEC NC_011742, E. coli O157:H7 EHEC NC_002695, E. coli 
APEC O1 CP000468, E. coli UTI89 ExPEC CP000243, E. coli CFTO73 ExPEC 
AE014075) using the CLC Genomics workbench software. Annotation of the resulting 
consensus sequences was done using RAST rapid annotations using subsystem technology 
(http://rast.nmpdr.org).
Phylogenetic analysis of fliC
We performed analysis using Phylogeny.fr (http://www.phylogeny.fr) one–click mode63 and 
the publicly available E. coli fliC gene sequences (E. coli strain B2F1 DQ459008.1, E. coli 
strain U11a–44 AY250004.1, E. coli O111:H– str.11128 AP010960.1, E. coli O113:H21 
DQ862122.1, E. coli ABU 83972 CP001671.1, E. coli VTH–15 GQ423574.1, E. coli 
CFT073 AE014075.1, E. coli 042 FN554766, E. coli O55:H7 str. CB961 CP001846.1, E. 
coli IHE3034 CP001969.1, E. coli O157:H7 str. Sakai NC_002695, E. coli HS CP000802, 
E. coli IAI39 NC_011750, E. coli UTI89 CP000243, E. coli S88 NC_011742, E. coli 
UMN026 CU928163.2, E. coli SMS–3–5 NC_010498, E. coli O127:H6 str. E2348 
NC_011601, E. coli APEC O1 NC_008563) and Legionella pneumophila flaA gene 
sequence as the outgroup NC_006368.1.
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IL-1R antibody experiments
We gave colony-born wild-type mice drinking water supplemented with AVNM for 7 d. We 
then gave mice given drinking water supplemented with AVNM and 5% DSS to induce gut 
injury. At 1, 24 and 48 h post DSS administration, we administered 100 μg of anti-IL-1R 
antibody (Amgen) i.p. or control IgG antibody to mice and and monitored survival (time to 
moribund) over the course of the disease.
Statistics
We analyzed Kaplan Meier plots using log rank analysis. All other data are expressed as 
mean +/− standard error of the mean and were analyzed using a Student's t-test or Mann 
Whitney test. We considered a P value less than 0.05 to be significant.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Antibiotic-treatment plus intestinal injury triggers a sepsis-like syndrome in wild-type 
mice
(a) Survival of wild-type male and female mice that received AVNM+5% DSS (n = 5) and 
5% DSS-only (n = 8). P = 0.0005 by Log rank analysis.
(b) Survival of wild-type male and female mice that received streptomycin+5% DSS (n = 6) 
and 5% DSS-only (n = 7). P = 0.2818 by Log rank analysis.
(c) Weight loss of wild-type male and female mice treated with 5% DSS compared to 
littermates that received drinking water supplemented with AVNM+5% DSS. Error bars 
indicate standard deviation; DSS-only (n = 9); AVNM+DSS (n = 9).
(d) Length of colons from wild-type male and female mice treated with 5% DSS compared 
to littermates that received drinking water supplemented with AVNM+5% DSS. Error bars 
indicate standard deviation. ***P = 0.0003 by Student's t-test. DSS-only (n = 4); AVNM
+DSS (n = 4).
(e) Representative cecums and colons at 4 d post DSS treatment initiation of wild-type male 
mice treated with 5% DSS, AVNM+5% DSS or water-treated (unmolested) control 
littermates.
(f) Representative images of small intestine at 4 d post DSS treatment initiation of wild-type 
male mice treated with 5% DSS, AVNM+5% DSS or water-treated (unmolested) control 
littermates.
(g) Rectal temperature of wild-type male and female mice treated with AVNM+DSS 
compared to littermates that received 5% DSS only. Error bars represent standard deviation. 
*P < 0.05 by Student's t-test. DSS-only (n = 8); AVNM/DSS (n = 5).
(h) Serum levels of blood urea nitrogen (BUN), creatine phosphokinase (CPK), alanine 
transaminase and aspartate transaminase (AST) at 3 d post DSS treatment initiation of wild-
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type male and female mice. Data are representative of two combined experiments. **P < 
0.01 and *P < 0.05 by Mann Whitney test. DSS-only (n = 7); AVNM/DSS (n = 7).
(i) Levels of culturable bacteria in the lung and liver of wild-type male and female mice 3 d 
post DSS treatment initiation. Data are representative of three independent experiments. *P 
< 0.05 by Student's t-test and (n = 4) for both conditions. Red dashed lines indicates limit of 
detection and black circles indicate individual mice below the limit of detection.
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Figure 2. Expansion and extraintestinal colonization of a multi-drug resistant E. coli in response 
to intestinal injury in dysbiotic mice
(a) Levels of AVNM-resistant bacteria in the intestinal-tract of AVNM-treated and water-
treated wild-type male and female littermates 7 d post treatment-initiation. *P < 0.05 by 
Student's t-test and (n = 4) for both conditions
(b) Levels of AVNM-resistant bacteria in the lung of AVNM- plus DSS-treated and DSS-
only treated male and female littermates 7 d post DSS treatment initiation. *P < 0.05 by 
Student's t-test and (n = 4) for both conditions. Red dashed line represents the limit of 
detection and black circles represent individual mice below the limit of detection.
(c) Levels of AVNM-resistant bacteria in the liver of AVNM- plus DSS-treated and DSS-
only treated male and female littermates 7 d post DSS treatment initiation. *P < 0.05 by 
Student's t-test and (n = 4) for both conditions
(d) Representative images of disc diffusion assays and quantitation of the zone of inhibition 
to determine the susceptibility of an E. coli-O21:H+ isolate to AVNM or streptomycin. E. 
coli-K12 was used as a control. Error bars indicate standard deviation.
(e) Intestinal levels of total AVNM-resistant bacteria and AVNM-resistant E. coli-O21:H+ 
in AVNM-treated wild-type male and female mice compared to littermates that received a 
water control. DSS-treated mice (n = 4) and AVNM+DSS-treated mice (n = 4). Red dashed 
line represents the limit of detection and black circles represent individual mice below the 
limit of detection.
(f) Lung and liver levels of total AVNM-resistant bacteria and AVNM-resistant E. coli-
O21:H+ in AVNM+DSS-treated wild-type male and female mice compared to littermates 
that received a DSS-only control. DSS-treated mice (n = 4) and AVNM+DSS-treated mice 
(n = 4).
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(g) Intestinal levels of AVNM-resistant E. coli and streptomycin-resistant E. coli in AVNM 
and streptomycin-treated wild-type male and female mice were determined and compared to 
wild-type littermates that received a water control. Unmolested mice (n = 4); AVNM treated 
mice (n = 4) and streptomycin treated mice (n = 4).
(h) Intestinal levels of AVNM-resistant E. coli in single-housed female Jax mice and Jax 
mice co-housed with female colony-born (CB) mice after 7 d of AVNM treatment. Jax 
single-housed (n = 3); Jax co-housed (n = 3) and CB co-housed (n = 3).
(i) Temperature and survival of AVNM+DSS-treated female single-housed Jax mice and Jax 
mice co-housed with female colony-born mice. For survival, P = 0.0236 by Log rank 
analysis. Data represent two combined experiments; Jax single-housed (n = 11), Jax co-
housed (n = 11); CB co-housed (n = 11) and DSS only (n = 5). Error bars indicate standard 
deviation.
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Figure 3. Systemic E. coli-O21:H+ infection is pathogenic in wild-type mice
(a) Survival of wild-type female mice injected with live or dead 5×108, 7.5×108 or 1×109 
live E. coli-O21:H+. P < 0.0001 for live vs. dead comparisons by Log rank analysis, (n = 5) 
females for all conditions.
(b) Rectal temperature of wild-type female mice injected with 5×108, 7.5×108 or 1×109 live 
or dead E. coli-O21:H+. At 6 h PI 1×109 live vs. 1×109 dead P = 0.0079, 7.5×108 live vs. 
7.5×108 dead P = 0.0079, at 24 h PI 5×108 live vs. 5×108 dead P = 0.0195. (n = 5) for all 
conditions.
(c) Wild-type female mice were inoculated with 5×108 live or dead E. coli-O21:H+ and 
serum levels of BUN, CPK, ALT and AST were analyzed 24 h post infection. (n = 4) for 
live infection and (n = 12) females for dead infection. *P < 0.05, **P < 0.01 and *** P < 
0.0005 by Student t-test and error bars indicate standard deviation.
(d) E. coli-O21:H+ CFUs in liver, lung, spleen and kidneys of wild-type female mice 
infected with 5×108 live bacteria at 24 and 48 h post infection. (n = 3) at both 24 h and 48 h 
PI and error bars indicate standard deviation.
(e) Survival of wild-type female mice infected with 5×108 live E. coli-O21:H+ or E. coli-
K12. P < 0.0001 by Log rank analysis. (n = 8) for both E. coli-O21:H+ and E. coli-K12 
injections.
(f) Rectal temperature of wild-type female mice infected with 5×108 live E. coli-O21:H+ or 
E. coli-K12. (n = 8) for both E. coli-O21:H+ and E. coli-K12 injections.
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Figure 4. Naip5-Nlrc4 mediates the pathogenesis of a sepsis-like syndrome in response to 
intestinal injury in dysbiotic mice
(a) Survival of wild-type and Nlrc4−/−Naip5−/− male and female fostermates treated with 
AVNM+5% DSS. Kaplan-Meier plot is representative of two experiments and P = 0.0003 
by log-rank analysis. Wild-type (n = 13) and Nlrc4−/−Naip5−/− (n = 14).
(b) Representative images of cecums and colons from wild-type and mutant female 
fostermates treated with AVNM+5% DSS at 3 d post DSS treatment initiation.
(c) Representative images of small intestines from AVNM+5% DSS treated wild-type and 
mutant female fostermates at 3 d post DSS treatment initiation.
(d) Rectal temperatures of wild-type and Nlrc4−/−Naip5−/− male and female fostermates 
treated with AVNM+5% DSS. Data are representative of three experiments. P < 0.05 by 
Student t-test. Wild-type (n = 10) and Nlrc4−/−Naip5−/− (n = 7).
(e) Serum BUN, CPK, AST and ALT levels at 2 d post DSS treatment initiation of wild-type 
and Nlrc4−/−Naip5−/− male and female fostermates treated with AVNM+5% DSS. Data are 
from three experiments and analyzed by Mann Whitney t-test. * P < 0.05. Wild-type (n = 3) 
and Nlrc4−/− Naip5−/− (n = 3).
(f) Levels of AVNM-resistant E. coli in the intestinal tracts of wild-type and 
Nlrc4−/−Naip5−/− male and female fostermates after 7 d of AVNM treatment. Wild-type (n = 
6) and Nlrc4−/−Naip5−/− (n = 4).
(g) Lung and liver levels of total AVNM-resistant E. coli-O21:H+ in AVNM+DSS-treated 
wild-type mice and AVNM+DSS-treated Nlrc4−/− Naip5−/− male and female fostermates 3 d 
post DSS treatment initiation. Black dots represent tissues isolated from mice that had no 
bacteria above the limit detection.
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Figure 5. E. coli-O21:H+ activates the Naip5-Nlrc4 inflammasome
(a) Motility agar was inoculated with wild-type, motile S. Typhimurium LT2, flagellin-
deficient S. Typhimurium ΔfliCΔfljB or E. coli-O21:H+ and incubated at 37 °C overnight. 
Representative images of the diffusion of motile bacteria are shown.
(b) Retroviral constructs expressing fliC from E. coli-O21:H+ or flaA from L. pneumophila 
followed by an IRES-GFP element or GFP alone were transduced into wild-type, Naip5−/−, 
or Nlrc4−/− macrophages, and the percentage of GFP-positive cells was enumerated by flow 
cytometry 4 d post-transduction.
(c) The percentage of cells expressing GFP from the retroviral lethality assay in (b) is 
indicated and charted.
Data are representative of three independent experiments.
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Figure 6. The Naip5-Nlrc4 inflammasome reduces host tolerance of a systemic E. coli infection
(a) Survival of female wild-type and Naip5−/−Nlrc4−/− mutant mice infected with 5×108 live 
E. coli. P = 0.0001 by Log rank analysis. Wild-type (n = 9) and Naip5−/−Nlrc4−/− (n = 11).
(b) Rectal temperature of female wild-type and Naip5−/−Nlrc4−/− mutant mice infected with 
5×108 live E. coli. Wild-type (n = 9) and Naip5−/−Nlrc4−/− (n = 11). *** P = 0.0003 by 
Mann-Whitney test.
(c) Intestinal pathology at 48 h post-infection of wild-type and Naip5−/−Nlrc4−/− mutant 
mice infected with 5×108 live E. coli.
(d) Serum levels of BUN, CPK, ALT and AST female wild-type and Naip5−/−Nlrc4−/− 
mutant mice infected with 5×108 live E. coli. at 24 h post-infection. *P < 0.05 by Mann-
Whitney test. Wild-type (n = 7) and Naip5−/−Nlrc4−/− (n = 6).
(e) in vivo infection of Caspase-1−/− and Il-1β−/− female mutant mice. Survival was 
monitored and compared to infected wild-type female mice. Infectious dose was 5×108 live 
E. coli O21:H+. For Caspase-1−/− P = 0.0025 and for Il-1β−/− P < 0.0001 by Log rank 
analysis. Wild-type (n = 9), Caspase-1−/− (n = 6) and Il-1β−/− (n = 12).
(f) Wild-type male and female mice were treated with AVNM for 7 d and then given 
AVNM+5% DSS. At 1, 24 and 48 h post DSS treatment initiation, mice were injected i.p. 
with 100 μg of α-IL-1R (n = 13) or control IgG antibody (n = 8) and survival was 
monitored. P = 0.0016 by Log rank analysis
(g) Wild-type and Naip5−/−Nlrc4−/− mutant female mice were infected with 5×108 live E. 
coli. At 24 and 48 h post infection, tissues were harvested, homogenized and analyzed for 
levels of E. coli colonization. Data were analyzed by Student t-test.
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